MECOM and myelodysplastic syndrome: [37] studied 120 patients with MECOM rearrangement: 38 (32%) presented with fewer than 20% bone marrow blasts and were classified as MDS, while 82 (68%) had more than 20% bone marrow blasts and were classified as AML.